MBRP on Reducing Craving and Addictive Behaviour in Adults
Launched by CHINESE UNIVERSITY OF HONG KONG · Jul 25, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a program called Mindfulness-Based Relapse Prevention (MBRP) to see if it can help adults in Hong Kong who struggle with substance abuse. The study aims to find out if this mindfulness approach can reduce cravings, improve mood, and enhance overall quality of life for participants. MBRP is an eight-week course that teaches skills to manage difficult feelings and situations without turning to drugs. Since mindfulness is already widely accepted and practiced in many communities, it could be a helpful and low-stigma option for those seeking support.
To be eligible for this trial, participants must be fluent in Cantonese, have received a substance use disorder diagnosis, and have completed treatment for substance abuse in the last six months. However, individuals with certain serious mental health issues or those at immediate risk of self-harm cannot participate. Those who join can expect to learn valuable mindfulness techniques in a group setting, which they can use even after the course ends to manage triggers and cravings. The study is currently recruiting participants and hopes to gather important insights on how mindfulness can support recovery from substance use disorders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fluent in Cantonese;
- • Has ever fulfilled the Structured Clinical Interview for DSM-IV/DSM-5 (SCID) drug module criteria for substance use disorder diagnoses; and
- • Has completed outpatient or inpatient treatment for substance abuse in the previous 6 months.
- Exclusion Criteria:
- • Inability to provide valid consent;
- • Current or lifetime psychotic disorder assessed by the Structured Clinical interview for DSM-IV/DSM-5;
- • Imminent suicidal risk; or
- • Dementia.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Samuel YS Wong
Principal Investigator
JCSPHPC, CUHK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials